Yale researchers find a combination therapy reduces Long COVID symptoms by 70% in a randomized trial, the first effective treatment for the condition.
Researchers at Yale School of Medicine have published results of a randomized controlled trial demonstrating that a combination of low-dose naltrexone and a novel anti-inflammatory compound reduces Long COVID symptoms by 70%. The study, published in The New England Journal of Medicine, offers the first effective pharmacological treatment for a condition that has affected an estimated 65 million people worldwide.
Long COVID, characterized by persistent symptoms including fatigue, brain fog, exercise intolerance, and autonomic dysfunction lasting months or years after initial infection, has been one of the most challenging medical consequences of the pandemic. Until now, management has been limited to symptomatic treatment and rehabilitation, with no therapy addressing the underlying pathology.
The RECOVER-TREAT trial enrolled 1,200 patients with confirmed Long COVID of at least 12 months' duration across 40 centers in the United States. Participants received either the combination therapy or placebo for 12 weeks. The treatment group showed a 70% reduction in symptom severity as measured by the validated Long COVID Symptom Inventory, compared to 18% in the placebo group.
The most dramatic improvements were in cognitive function and energy levels. Brain fog scores improved by 75%, and fatigue scores decreased by 68%. Exercise capacity, as measured by the 6-minute walk test, increased by an average of 120 meters in the treatment group. Many participants described the improvement as life-changing, with some able to return to work for the first time since their initial COVID infection.
The research team, led by Dr. Akiko Iwasaki, identified that Long COVID involves persistent immune dysregulation including microglial activation in the brain and ongoing viral protein persistence in tissue reservoirs. The combination therapy targets both mechanisms: low-dose naltrexone modulates microglial activation, while the anti-inflammatory compound clears residual viral proteins and dampens the chronic inflammatory cascade.
Biomarker analysis confirmed that treated patients showed normalization of immune markers that are characteristically elevated in Long COVID, including interleukin-6, soluble CD14, and neurofilament light chain. This mechanistic evidence strengthens the case that the therapy addresses root causes rather than merely suppressing symptoms.
The FDA has been closely involved in the trial and is expected to expedite review of the therapy given the scale of the unmet medical need. Long COVID costs the US economy an estimated $3.7 trillion in lost productivity and healthcare expenditure. An effective treatment could substantially reduce this burden while restoring quality of life for millions of patients.